Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: The most prominent feature of melancholic depression is a near-total loss of the capacity to derive pleasure from activities or other positive stimuli. Additional symptoms can include psychomotor disturbances, anorexia, excessive guilt, and early awakening from sleep. Melancholic patients may exhibit treatment responses and outcomes that differ from those of non-melancholic patients. Pooled data from double-blind, placebo-controlled studies were utilized to compare the efficacy of duloxetine in depressed patients with and without melancholic features. Methods: Efficacy data were pooled from 8 double-blind, placebo-controlled clinical trials of duloxetine. The presence of melancholic features (DSM-IV criteria) was determined using results from the Mini International Neuropsychiatric Interview (MINI). Patients (aged ≥ 18 years) meeting DSM-IV criteria for major depressive disorder (MDD) received duloxetine (40–120 mg/d; melancholic, N = 759; non-melancholic, N = 379) or placebo (melancholic, N = 519; non-melancholic, N = 256) for up to 9 weeks. Efficacy measures included the 17-item Hamilton Rating Scale for Depression (HAMD 17) total score, HAMD 17 subscales (Maier, anxiety, retardation, sleep), the Clinical Global Impression of Severity (CGI-S) and Patient Global Impression of Improvement (PGI-I) scales, and Visual Analog Scales (VAS) for pain. Results: In data from all 8 studies, duloxetine's advantage over placebo did not differ significantly between melancholic and non-melancholic patients (treatment-by-melancholic status interactions were not statistically significant). Duloxetine demonstrated significantly greater improvement in depressive symptom severity, compared with placebo, within both melancholic and non-melancholic cohorts (p ≤ .001 for HAMD 17 total score, CGI-S and PGI-I). When analyzed by gender, the magnitude of improvement in efficacy outcomes did not differ significantly between duloxetine-treated male and female melancholic patients. In the two studies that assessed duloxetine 60 mg once-daily dosing, duloxetine-treated melancholic patients had significantly greater improvement compared with placebo on HAMD 17 total score, CGI-S, PGI-I, 3 of 4 subscales of the HAMD 17, and VAS overall pain severity (p < .01). Estimated probabilities of response and remission were significantly greater for melancholic patients receiving duloxetine 60 mg QD compared with placebo (response 74.7% vs. 42.2%, respectively, p < .001; remission 44.4% vs. 24.7%, respectively, p = .002 Conclusions: In this analysis of pooled data, the efficacy of duloxetine in patients with melancholic features did not differ significantly from that observed in non-melancholic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gold, P. W., & Chrousos, G. P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001032 · Cited by 1,274
Anderson, I. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00092-0 · Cited by 940 · cited 7×
“Some studies have demonstrated advantages for TCAs over SSRIs in the treatment of melancholia [29-32], and these results have found support from patient-rated assessments of antidepressant efficacy.”
BackgroundInfluentialDetke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384
Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334 · cited 1×
“Detailed safety and efficacy results from Studies 1 [39], 4 [40], 5 [41], and 6 [42] have been published previously.”
BackgroundSelf-citationGoldstein, D. J., Lu, Y., Detke, M. J., Wiltse, C., Mallinckrodt, C., & Demitrack, M. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000132448.65972.d9 · Cited by 314
Self-citationInflammatory markers in major depression and melancholia.
Rothermundt, M., Arolt, V., Peters, M., Gutbrodt, H., Fenker, J., Kersting, A., & Kirchner, H. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00157-9 · Cited by 174
Impaired In Vivo Immune Responses in Patients with Melancholia
Hickie, I., Hickie, C., Lloyd, A., Silove, D., & Wakefield, D. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.162.5.651 · Cited by 75 · cited 1×
“When compared with non-melancholic depressed patients, melancholics have also been shown to exhibit lower concentration of nighttime serum melatonin [15], lower plasma serotonin (5-HT) concentrations [16,17], and an impaired in vivo immune response [18,19].”
ResultParker, G., Hadzi-Pavlovic, D., Austin, M.-P., Mitchell, P., Wilhelm, K., Hickie, I., Boyce, P., & Eyers, K. (1995) · Psychological Medicine · doi:10.1017/s0033291700035066 · Cited by 57 · cited 2×
“In reviewing a number of long-term studies, Parker et al concluded that melancholics appear to respond well to treatment of individual episodes but have frequent recurrences, while non-melancholics may respond less rapidly and less completely in any individual episode but show a general pattern of improvement over tim…”
MethodKasper, S., Möller, H. J., Montgomery, S. A., & Zondag, E. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199501004-00001 · Cited by 37
Cited by
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“Despite much investigation, consistent empirical associations between melancholic features and superior response to antidepressant medication have not been established (Dodd and Berk, 2004; Georgotas et al., 1986; Mallinckrodt et al., 2005; Nierenberg, 2003; Peselow et al., 1992; Souery et al., 2007; Trivedi et al., 2…”
BackgroundEhntholt, K. A., & Yule, W. (2006) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2006.01638.x · Cited by 494
Psychomotor retardation in depression: Biological underpinnings, measurement, and treatment
Buyukdura, J. S., McClintock, S. M., & Croarkin, P. E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.10.019 · Cited by 398
Lafarga, T., & Hayes, M. (2014) · Meat Science · doi:10.1016/j.meatsci.2014.05.036 · Cited by 392
Psychiatric Disorders and Sleep
Krystal, A. D. (2012) · Neurologic Clinics · doi:10.1016/j.ncl.2012.08.018 · Cited by 386
Metadata
- Authors
- Mallinckrodt, C. H., Watkin, J. G., Liu, C., Wohlreich, M. M., & Raskin, J.
- Venue
- BMC Psychiatry
- Published
- 2005-01-04
- Volume
- 5
- Issue
- 1
- Pages
- 1-1
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W2107832668
- Cited by
- 134
- References
- 9
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features. https://app.cochat.ai/papers/10.1186/1471-244x-5-1
- The paper
- Mallinckrodt, C. H., Watkin, J. G., Liu, C., Wohlreich, M. M., & Raskin, J. (2005). Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features. BMC Psychiatry. https://doi.org/10.1186/1471-244x-5-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.